Cerebral Palsy and Sleep Apnea in North Part of Finland
Obstructive sleep apnoea is a risk factor for cerebral palsy. study hypothesis: In prospective study the investigators want to know how many cerebral palsy patients have sleep apnoea and does thrombolysis play a role in severity of osa in six months follow up.
|Study Type:||Observational [Patient Registry]|
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Target Follow-Up Duration:||6 Months|
|Official Title:||Obstructive Sleep Apnea as a Risk Factor for Cerebral Palsy, a Prospective Study|
- cerebral palsy events and severity of osa [ Time Frame: from six months to twenty four months ] [ Designated as safety issue: No ]in prospective study outcome measure is severity of osa in 6months follow-up
|Study Start Date:||April 2013|
|Estimated Study Completion Date:||November 2014|
|Estimated Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
Nasal-cpap treatment and compliance in sleep apnea patients with cerebral palsy.
No Nasal-cpap treatment in sleep apnea patients with cerebral palsy. Severity of sleep apnea in thrombolysis patients and in control patients. Thrombolysis reduces severity of sleep apnea.Sleep apnea is common among cerebral palsy patients.
No nasal-cpap in sleep apnea patients with cerebral palsy
In prospective study the investigators include all over 18 years old patients who came to emergency room for cerebral palsy.Exclusion criteria is not able to co-operate or need for intensive care unit.The investigators shall take 100 control patients who have cerebral palsy and no thrombolysis and 100 study patients who will have thrombolysis. The investigators do sleep registration during hospital staying within 2 days after patients have felt ill.Follow-up registration will be done after 6 months at home.
|Contact: Jaana Huhtakangas, MDfirstname.lastname@example.org|
|Contact: Juha Huhtakangas, MD, PhDemail@example.com|
|Oulu university hospital,department of neurology||Recruiting|
|Oulu, northern Finland, Finland, 90029|
|Contact: Juha Huhtakangas, Md PhD +35883154032 firstname.lastname@example.org|
|Contact: Jaana huhtakangas, Md +358083154038 email@example.com|
|Study Director:||Tarja Saaresranta, Md PhD||University hospital of Turku|